EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.
ConditionMigraine Disorders
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorIRCCS San Raffaele Roma
About this trial
The object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population.
Eligibility criteria
Qualifiers
Age between 18 and 75 years;
Males and females;
Willingness to sign the informed consent;
High frequency episodic migraine, at least 8 days per month of disabling migraine in the past 3 months;
Disqualifiers
Other headaches different than migraine;
Known intolerance to eptinezumab or eccipients;
Current treatment with other mAbs;
Vascular disease or Raynaud.
Trial design
Treatments tested in this trial
- Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution
Treatment groups
No treatment groups listed
Locations
1IRCCS San Raffaele Roma00163, RomaRM, Italy
Sponsors and collaborators
IRCCS San Raffaele Roma
Lead sponsor
Source ClinicalTrials.gov